EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of a Novel and Potent Kir4.1 Inhibitor as a Safe and Rapid‐Onset Antidepressant Agent in Mice

Sisi Wang, Xiaoyu Zhou, Mengdan Li, Chao Zhang, Haiyan Xu, Jingyi He, Li Zhan, Yueling Gu, Hao Gu, Tianyu Tu, Hanfang Liu, Taotao Lu und 4 weitere

Advanced Science · 2026

DOI: 10.1002/advs.202509506 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Sisi Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioreactor Engineering, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Frontiers Science Ce…. Hauptthemen laut MEDLINE: Antidepressive Agents, Potassium Channels, Inwardly Rectifying, Major Depressive Disorder, Depression. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National key R&D Program of China, Strategic Priority Research Program of the Chinese Academy of Sciences, National Science Fund for Distinguished Young Scholars.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Major depressive disorder is a serious psychiatric disorder for which novel and fast‐acting antidepressants are required. Targeted inhibition of the astrocytic inwardly rectifying potassium channel 4.1 (Kir4.1) in the lateral habenula could rapidly alleviate depression‐like behaviors. A previous study identified Kir4.1 as a promising target for achieving rapid‐onset antidepressant effects. The aim of this study is to identify novel Kir4.1 inhibitors with good druggability through structural modification of the lead compound EHop‐016, resulting in fifty derivatives. Among these, JX3212 exhibits the most potent in vitro inhibitory activity against Kir4.1, with acceptable selectivity and excellent brain exposure. Notably, a single administration of JX3212 results in rapid‐onset antidepressant effects within 1 h in multiple rodent models of depression, with comparable efficacy to ( S )‐ketamine; this inhibitor‐like effect is abolished in mice with tamoxifen‐induced conditional Kir4.1 knockout in astrocytes. Additionally, JX3212 demonstrates superior safety margins compared to both ( S )‐ketamine and the conventional antidepressant imipramine in murine behavioral assays. In summary, JX3212 functions as a selective Kir4.1 inhibitor with favorable druggability and stable antidepressant efficacy in preclinical models. This pharmacological profile supports the further development of JX3212 as a promising therapeutic candidate for major depressive disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive AgentsPotassium Channels, Inwardly RectifyingMajor Depressive DisorderDepressionAnimalsMiceKcnj10 ChannelDisease Models, AnimalMaleHumansMice, Inbred C57BLMice, KnockoutAstrocytes

Stichwörter der Autor:innen

(S)‐ketamineKir4.1 inhibitorsdepressionrapid‐onsetstructural repurposing

Substanzen

Antidepressive AgentsPotassium Channels, Inwardly RectifyingKcnj10 Channel

Autor:innen und Institutionen

  • State Key Laboratory of Bioreactor Engineering, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Frontiers Science Center for Materiobiology and Dynamic Chemistry, Shanghai Key Laboratory…
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • School of Pharmacy, Henan University, Kaifeng, 475004, China.
  • Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Haikou, 570228, China.
  • Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, School of Pharmacy, Shihezi University, Shihezi, 832003, China.
  • Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528437, China.

ORCID-Profile: Jian Li

Förderung

  • National key R&D Program of China
  • Strategic Priority Research Program of the Chinese Academy of Sciences
  • National Science Fund for Distinguished Young Scholars
  • Shanghai Frontier Science Center of Optogenetic Techniques for Cell Metabolism
  • Chinese Special Fund for State Key Laboratory of Bioreactor Engineering
  • Innovative Research Team of High-level Local University in Shanghai
  • Postdoctoral Research Foundation of China
  • National Postdoctoral Program for Innovative Talents

Zitieren

APA

Wang, S., Zhou, X., Li, M., Zhang, C., Xu, H., He, J., Zhan, L., Gu, Y., Gu, H., Tu, T., Liu, H., Lu, T., Zheng, Y., Li, J., Gao, Z., & Xu, Y. (2026). Discovery of a Novel and Potent Kir4.1 Inhibitor as a Safe and Rapid‐Onset Antidepressant Agent in Mice. Advanced Science. https://doi.org/10.1002/advs.202509506

Vancouver

Wang S, Zhou X, Li M, Zhang C, Xu H, He J, et al. Discovery of a Novel and Potent Kir4.1 Inhibitor as a Safe and Rapid‐Onset Antidepressant Agent in Mice. Advanced Science. 2026. doi:10.1002/advs.202509506

BibTeX
@article{Wang2026,
  author = {Wang, Sisi and Zhou, Xiaoyu and Li, Mengdan and Zhang, Chao and Xu, Haiyan and He, Jingyi and Zhan, Li and Gu, Yueling and Gu, Hao and Tu, Tianyu and Liu, Hanfang and Lu, Taotao and Zheng, Yueming and Li, Jian and Gao, Zhaobing and Xu, Yixiang},
  title = {Discovery of a Novel and Potent Kir4.1 Inhibitor as a Safe and Rapid‐Onset Antidepressant Agent in Mice},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202509506}
}
Kostenlos starten →